Compare ARDC & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARDC | PROF |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.3M | 270.7M |
| IPO Year | 2011 | 2017 |
| Metric | ARDC | PROF |
|---|---|---|
| Price | $11.99 | $6.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 127.0K | ★ 357.8K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | N/A | ★ 1.41 |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | N/A | $115.41 |
| Revenue Next Year | N/A | $60.63 |
| P/E Ratio | ★ N/A | $4.56 |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $11.52 | $3.90 |
| 52 Week High | $15.03 | $8.95 |
| Indicator | ARDC | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 36.82 | 53.73 |
| Support Level | N/A | $5.75 |
| Resistance Level | $13.55 | $7.08 |
| Average True Range (ATR) | 0.17 | 0.45 |
| MACD | 0.03 | 0.17 |
| Stochastic Oscillator | 47.50 | 83.43 |
Ares Dynamic Credit Allocation Fund Inc is a closed-ended, diversified management investment company. The fund's investment objective is to provide an attractive level of total return, through current income and, secondarily, through capital appreciation. The Fund invests in a broad, dynamically managed portfolio of senior secured loans (Senior Loans) made to companies whose debt is rated below investment grade; corporate bonds (Corporate Bonds) that are high yield issues rated below investment grade; other fixed-income instruments of a similar nature that may be represented by derivatives; and securities of collateralized loan obligations (CLOs).
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.